icon-folder.gif   Conference Reports for NATAP  
 
  63rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 9-12 2012
Back grey_arrow_rt.gif
 
 
 
Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting)
 
 
  Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
 
C Hezode1, C Dorival2, F Zoulim3, D Larrey4, S Pol5, P Cacoub6, V Canva7, T Poynard8, D Samuel9, M Bourliere10, L Alric11, JJ Raabe12, JP Zarski13, G Riachi14, PH Bernard15, V de Ledinghen16, V Loustaud-Ratti17, S Metivier18, X Causse19, P Marcellin20, Y Barthe2, H Fontaine5, F Carrat2, JP Bronowicki21 for the CUPIC study group (ANRS CO 20)
 
Hopital Henri Mondor, Creteil, 2. UMR-S 707, Paris, 3. INSERM U871, Lyon, 4. Hopital Saint-Eloi, Montpellier, 5. Hopital Cochin, Paris, 6. Medecine interne, Hopital de la Pitie-Salpetriere, Paris, 7. Hopital Claude Huriez, Lille, 8. Hepatologie, Hopital de la Pitie-Salpetriere, Paris, 9. Hopital Paul Brousse, Villejuif, 10. Fondation Hopital Saint Joseph, Marseille, 11. Medecine interne, Hopital Purpan, Toulouse, 12. Hopital Bon Secours, Metz-Thionville, 13. Hopital Albert Michallon, Grenoble, 14. Hopital Charles Nicolle, Rouen, 15. Hopital Saint Andre, Bordeaux, France. 16. Hopital Haut Leveque, Bordeaux, 17. Hopital Dupuytren, Limoges, 18. Hepatologie, Hopital Purpan, Toulouse, 19. Hopital de La Source, Orleans, 20. Hopital Beaujon, Beaujon, 21. Hopital de Brabois, Nancy, France.

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif